Results 11 to 20 of about 133,417 (336)

MicroRNA-330-5p as a putative modulator of neoadjuvant chemoradiotherapy sensitivity in oesophageal adenocarcinoma [PDF]

, 2015
Oesophageal adenocarcinoma (OAC) is the sixth most common cause of cancer deaths worldwide, and the 5-year survival rate for patients diagnosed with the disease is approximately 17%.
Bibby, Becky A S, Bibby, Becky A. S., Maher, Stephen G., Reynolds, John V.   +3 more
core   +11 more sources

The effects of cancer therapies on physical fitness before oesophagogastric cancer surgery: a prospective, blinded, multi-centre, observational, cohort study [version 1; peer review: 2 approved]

NIHR Open Research, 2021
Background: Neoadjuvant cancer treatment is associated with improved survival following major oesophagogastric cancer surgery. The impact of neoadjuvant chemo/chemoradiotherapy on physical fitness and operative outcomes is however unclear.
Lisa Loughney, Gareth Ambler, Thomas Owen, Michael G. Mythen, Denny Z.H. Levett, Gerard Danjoux, Jamie J. Kelly, Peter M.A. Calverley, Michael P.W. Grocott, Sandy Jack, Zachos Anastasiou, Malcolm A. West   +11 more
doaj   +1 more source

Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: role, controversy, and future directions. [PDF]

, 2018
BackgroundThe value of induction chemotherapy (ICT) remains under investigation despite decades of research. New advancements in the field, specifically regarding the induction regimen of choice, have reignited interest in this approach for patients with
Cohen, EEW, Haddad, RI, Hitt, R, Lefebvre, J-L, Posner, M, Schulten, J, Vermorken, JB   +6 more
core   +1 more source

Comparison of Induction Chemotherapy Plus Concurrent Chemoradiotherapy and Concurrent Chemoradiotherapy Alone in Locally Advanced Nasopharyngeal Carcinoma

Technology in Cancer Research & Treatment, 2021
Purpose: Induction chemotherapy plus concurrent chemoradiotherapy and concurrent chemoradiotherapy alone are both standard treatment regimens for managing locally advanced nasopharyngeal carcinoma.
Guoqiang Xu MD, Qiaoli Wang MD, Xingrao Wu MD, Chunyan Lv MD, Guilin Zeng MD, Zhihong Xue MD, Ruixue Cao MD, Nan Zhang BD, Wei Xiong PhD, Qin Huang MD   +9 more
doaj   +1 more source

Efficacy of Chemotherapy in Survival of Stage I Nasopharyngeal Carcinoma

Frontiers in Oncology, 2021
PurposeTo identify whether chemoradiotherapy improves survival of stage I nasopharyngeal carcinoma (NPC).Materials and MethodsNPC patients were extracted from the Surveillance, Epidemiology, and End Results database between 2010 and 2015.
Jia-Lin Ma, Shi-Ting Huang, Yan-Ming Jiang, Xin-Bin Pan   +3 more
doaj   +1 more source

CHEMORADIOTHERAPY FOR COLORECTAL CANCER [PDF]

Gut, 2005
Recent estimates for cancer incidence and mortality in Europe continue to rank colorectal cancer as the second most common cause for cancer related death. Every year more than 376 000 patients are newly diagnosed with colorectal cancer and approximately 200 000 people die from the disease.1 Even though these numbers show a slight decrease,2,3 partially
N Andre, Wolff Schmiegel
openaire   +2 more sources

The Utility of Ultrasonography in the Diagnosis of Cervical Lymph Nodes after Chemoradiotherapy for Head and Neck Squamous Cell Carcinoma

Medicina, 2021
Background and Objectives: There is evidence or consensus on the use of 18F-2-fluorodeoxyglucose-positron emission tomography with computed tomography (PET-CT) in evaluating the effects of treatment at 12 weeks after chemoradiotherapy for head and neck ...
Hoshino Terada, Yuzo Shimode, Madoka Furukawa, Yuichiro Sato, Nobuhiro Hanai   +4 more
doaj   +1 more source

Induction chemotherapy in the treatment of nasopharyngeal carcinoma: Clinical outcomes and patterns of care [PDF]

, 2018
The role of induction chemotherapy in nasopharyngeal carcinoma (NPC) remains controversial. The primary aim of this study was to use the National Cancer Database to evaluate the patterns of care of induction chemotherapy in NPC and its impact on overall ...
Adkins, Douglas, Barnes, Justin, Daly, Mackenzie D, Gabani, Prashant, Gay, Hiram A, Lin, Alexander J, Oppelt, Peter, Rich, Jason T, Rudra, Soumon, Thorstad, Wade L, Zevallos, Jose P   +10 more
core   +2 more sources

Nimotuzumab combined with chemoradiotherapy for the treatment of cervical cancer: A meta-analysis of randomized controlled trials

Frontiers in Oncology, 2022
ObjectivesTo assess the clinical efficacy and toxicity of nimotuzumab in combination with chemoradiotherapy or chemoradiotherapy alone in the treatment of cervical cancer.MethodsThe PubMed, Embase, Cochrane Library, Web of Science, China National ...
Yan Yuan, Yan Yuan, Jiuzhou Chen, Jiuzhou Chen, Miao Fang, Miao Fang, Yaru Guo, Yaru Guo, Xueqing Sun, Xueqing Sun, Dehong Yu, Yilong Guo, Yong Xin, Yong Xin   +13 more
doaj   +1 more source

Proline-rich protein 11 overexpression is associated with a more aggressive phenotype and poor overall survival in ovarian cancer patients

World Journal of Surgical Oncology, 2020
Background The proline-rich protein 11 (PRR11) is a newly identified oncogene associated with a poor prognosis in several human cancers. Nonetheless, research on its role in ovarian cancer (OC) remains largely understudied.
Yu Zhan, Xueyuan Wu, Gang Zheng, Jingjing Jin, Chaofu Li, Guanzhen Yu, Wenfeng Li   +6 more
doaj   +1 more source